Investment Rating - The report downgrades Booz Allen Hamilton (BAH) to Sell from Neutral, indicating limited revenue and earnings growth potential in the medium term, with valuation still having downside risk [1][45]. Core Insights - Medium-term revenue growth is expected to be closer to flat due to pressure on federal civilian spending and shifting priorities within the Department of Defense (DoD) [1][2]. - Margin pressures are anticipated as the industry shifts towards more outcomes-based contracting and fixed-price contracts, which could increase risk for contractors [3][31]. - BAH's current trading multiples are 17X P/E and 12X EBITDA on CY26E, which are in line with historical averages but could decline further if earnings remain flat [4][41]. Revenue Outlook - Federal civilian agency budgets are under pressure, leading to expectations of organic revenue growth for BAH being closer to flat for the next several years [2][18]. - The company reported a book-to-bill ratio of 0.71X for the March 2025 quarter, indicating potential challenges in securing new contracts [17][25]. Margin Analysis - The industry is experiencing a shift towards more fixed-price contracts, which may lead to increased competition and pressure on margins [3][31]. - Historical trends show that during periods of revenue pressure, margins in the government services industry have declined due to increased price competition [31][34]. Valuation Metrics - BAH's valuation metrics indicate it trades at 17X CY26E P/E and 12X CY26E EBITDA, which are consistent with its 15-year historical average [4][41]. - The report suggests that if growth and margin pressures continue, BAH's valuation could decline further [4][41]. Financial Projections - The report provides revised financial forecasts for BAH, with expected revenues of $12,220 million for FY26 and $12,342 million for FY27, reflecting lower organic growth assumptions [40]. - Adjusted EBITDA is projected at $1,335 million for FY26 and $1,337 million for FY27, indicating a downward revision from previous estimates [40][45].

Investment Rating - The report downgrades Sipchem to Neutral from Buy due to limited earnings upside and full valuation [3][62]. Core Insights - The energy sector is experiencing a lower-for-longer oil price environment, with oil prices dropping approximately 13% since the start of the year to US$65/bbl, and forecasts suggest an average of US$64/bbl for 2025 and 2026 [1][34]. - The report favors GCC upstream/midstream names, particularly Abu Dhabi energy companies, which are better positioned to weather market volatility due to secured growth potential and advantageous contractual frameworks [2][34]. - In the chemicals sector, fertilizers are preferred due to strong demand dynamics, while caution is advised on petrochemicals due to high uncertainty and oversupply concerns [3][62]. Summary by Sections Energy Sector - The report highlights a preference for Abu Dhabi energy names due to their regulated returns and visible growth potential, with companies like ADNOC Drilling, ADNOC Gas, and Saudi Aramco rated as Buy [2][36]. - GCC energy names have shown strong year-on-year growth, with an average EBITDA consensus beat of approximately 6%, although share price performance has been muted [35][38]. - The report notes that the UAE's natural gas supply is expected to grow significantly, with Saudi Aramco aiming to increase gas production by over 60% by 2030 [12][54]. Chemicals Sector - The ME&A chemicals sector has underperformed, down approximately 11% year-to-date, with a notable decline in share prices for companies like Sipchem and Kayan [20][62]. - The report indicates that while margins are expected to expand in the second quarter, a weak macro backdrop could pressure earnings into the second half of 2025 [22][67]. - Companies with balanced product exposure and those benefiting from shareholder returns have fared better, while Sipchem is seen as less likely to benefit from a lower oil price environment due to its high fixed feed component [62][63].

Investment Ratings - AMEC: Buy, Rmb173.13 [36] - ASMPT: Neutral, HK$52.35 [36] - EHang: Buy, $16.96 [36] - Horizon Robotics: Buy, HK$7.92 [36] - Huaqin Technology: Buy, Rmb66.75 [36] - Kingsoft Office: Buy, Rmb278.50 [36] - Lingyi: Buy, Rmb7.98 [36] - Maxscend: Neutral, Rmb70.46 [36] - SICC: Buy, Rmb61.45 [36] - StarPower: Neutral, Rmb80.89 [36] - Sunny Optical: Neutral, HK$60.95 [36] - VeriSilicon: Buy, Rmb83.27 [36] Core Insights - The report highlights the rising demand for AI inferencing driven by enhanced foundation models and the localization of semiconductor technologies in China [1] - There is a positive outlook for the semiconductor industry in China, with continuous R&D investment and capacity expansions despite geopolitical uncertainties [2] - Companies like VeriSilicon and AMEC are expanding their product offerings to meet the growing demand for AI devices and local production needs [3][8] - The commercialization of Robotaxi and advancements in smart driving technologies are expected to drive growth in the automotive sector [1] - AI applications are expanding, with a focus on monetization of consumer and business AI tools [1] Semiconductor Sector - Continuous R&D progress is noted in semiconductor technologies, with a focus on lithography systems and local capacity expansions [2] - VeriSilicon is expanding into GPU IP and AI IP to meet rising AI demand [3] - AMEC is optimistic about local production contributions and is expanding its addressable market through product migrations [8] - SICC anticipates increased demand for SiC substrates driven by the growth of EVs and AR glasses [10] AI and Consumer Electronics - Huaqin expects double-digit revenue growth in 2025, driven by its data center and consumer electronics businesses [17] - Lingyi is focusing on growth in foldable phone components and cooling components for AI servers [16] - Kingsoft Office is enhancing its AI capabilities to support enterprise clients and expand its user base [26] Smart Driving and Robotaxi - Horizon Robotics is set to mass-produce its HSD system in 2025, supporting advanced driving features [20] - EHang is accelerating deliveries of its EH216-S model and expanding its production capacity [21][22] - ECARX is focusing on smart driving solutions, achieving significant revenue growth [23] AI Software - Kingsoft Office is enhancing its AI features to attract more users and expand its market presence [26] - Meitu is optimistic about the growth of AI productivity tools and improving content generation capabilities [27] - Sensetime is focusing on generative AI trends and has launched a new foundation model with competitive features [28]

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/ ...

Update on new LTC hospitals: Management mentioned its plan is to increase number of operating beds at Madina LTC and Dammam LTC and expects patient growth through the year. Guidance on bed capacity and capex: Management disclosed plans to add c.500 beds, taking total capacity to c.2,100 in FY26 from c.1,600 currently. It expects capex to come in at SR1bn in FY25. Revenue growth came in at 5.8% yoy in 1Q25 driven by higher OPD visits, higher occupancy rates in inpatient departments and positive impact from i ...

Investment Rating - The report maintains a Buy rating on AstraZeneca (AZN) and a Sell rating on Roche (ROG) [8] Core Insights - The SERD (Selective Estrogen Receptor Degrader) class of breast cancer therapies is expected to be a significant focus for investors, with a potential market value exceeding $15 billion by 2035 due to a global patient population of over 500,000 [1] - AstraZeneca's camizestrant is projected to achieve peak sales of $5.5 billion, while Roche's giredestrant is forecasted to reach $4.8 billion [2] - The SERENA-6 trial for camizestrant is anticipated to present pivotal data at ASCO in June 2025, which could serve as a catalyst for market recognition of its unique positioning [2][3] Market Dynamics - The report highlights that camizestrant is well-positioned to become the leading second-generation oral SERD, particularly due to its trial design and early patient treatment strategy [2][7] - The potential for camizestrant to capture a 30% market penetration in the US is based on its clinical strategy of treating patients before disease progression, contrasting with competitors targeting post-progression patients [22] Clinical Trial Insights - The SERENA-6 trial is expected to demonstrate a progression-free survival (PFS) of at least 12 months, with a bull case scenario projecting 17 months [3][19] - Camizestrant's design differentiates it from competitors by enrolling patients who have developed ESR1 mutations without disease progression, which may lead to better clinical outcomes [11][17] - Safety concerns regarding camizestrant, particularly cardiac and ocular adverse events, are noted but are not seen as significant issues due to low discontinuation rates in earlier trials [13][17] Sales Forecasts - The report estimates that camizestrant could generate approximately $1 billion in global peak sales from the SERENA-6 trial, with an increase from previous estimates due to its earlier treatment strategy [22][23] - The consensus estimate for camizestrant's unrisked peak sales is around $5.2 billion, with the report's estimate slightly higher at $5.5 billion [23] Competitive Landscape - The report discusses the competitive positioning of camizestrant against other SERDs, emphasizing its superior bioavailability and lack of significant drug-drug interactions, which may enhance its use in combination therapies [14][15] - The potential for camizestrant to be preferred over other SERDs in clinical practice is supported by its trial design and efficacy data [16][17] Future Considerations - The report anticipates that the outcomes of the SERENA-6 trial will influence the sequencing of SERD therapies in clinical practice, particularly regarding the timing of treatment initiation based on ESR1 mutation detection [20][32] - The upcoming data releases from related trials, including ROG's persevERA, are expected to provide further insights into the competitive dynamics of the SERD market [27]

28 May 2025 | 6:45AM IST Info Edge India Ltd. (INED.BO) Buy Earnings Review: Good growth but at the cost of margins; outlook robust; Buy INED.BO 12m Price Target: Rs1,720.00 Price: Rs1,454.65 Upside: 18.2% Info Edge management struck a constructive tone on forward growth outlook, though it expects continued reinvestments in the business in the near term; this was similar to its 4QFY25 print, where EBITDA growth of 5% YoY sharply missed GSe though revenue growth of 13% YoY was robust and in line. We highligh ...

Entel SA (ENTEL.SN) Trimming Estimates Post-1Q25 27 May 2025 | 5:20PM BRT | ENTEL.SN | | --- | | 12m Price Target: Ch$3,450 | | Price: Ch$2,791 | | Upside: 23.6% | We incorporate 1Q25 earnings as well as updated macro/FX assumptions, lowering estimates particularly in Chile, given i) somewhat more-conservative ARPU assumptions amid continued competitive pressure from AMX and WOM in mobile, though we already assumed some increased competition this year; ii) weaker-than-expected fiber trends, with management ...

27 May 2025 | 9:20PM EDT Okta (OKTA) 1QFY: Muted quarterly trends reignite debate on path to stable growth n Okta sees multiple ways to benefit from the increasing adoption of AI Agents at its customers. Auth for GenAI is in developer preview (expected GA soon), and is designed to help developers build AI Agents/workflows. Additionally, AI Agents have resulted in more non-human identities within Gabriela Borges, CFA +1(212)902-7839 | gabriela.borges@gs.com Goldman Sachs & Co. LLC Callie Valenti +1(212)357-2 ...

Investment Rating - The investment rating for Sarepta Therapeutics Inc. (SRPT) is "Buy" with a 12-month price target of $100, indicating a potential upside of 160.8% from the current price of $38.35 [8][9]. Core Insights - The commentary from the newly-appointed FDA CBER Director, Dr. Vinay Prasad, suggests that the full approval of Elevidys for ambulatory patients is likely to remain intact, barring any serious safety events [1][6]. - There is a risk to Elevidys' accelerated approval in non-ambulatory patients, which constitutes approximately half of the market, depending on confirmatory data expected in 2027 [1][6]. - The company has projected $13 billion in free cash flow by the end of 2030 and is focusing on pipeline diversification, including early Phase 1 data in other muscular dystrophies [1]. Financial Projections - Revenue projections for SRPT are estimated to grow from $1.9 billion in 2024 to $4.3 billion by 2027 [9]. - The EBITDA is expected to improve significantly, moving from a loss of $102.6 million in 2025 to a profit of $2.1 billion by 2027 [9]. - The forecasted Free Cash Flow yield is projected to increase from -2.8% in 2024 to 64.0% by 2027 [9]. Regulatory Environment - The new CBER Director emphasized the importance of regulatory flexibility in rare diseases and gene therapy, indicating a supportive stance towards maintaining previous approvals unless new safety concerns arise [2][6]. - The Director's approach suggests that accelerated approval pathways will continue to be utilized, particularly in the context of rare diseases and oncology [6]. Market Context - The market capitalization of SRPT is currently $3.7 billion, with an enterprise value of $3.3 billion [9]. - The company is facing competitive risks as other firms are also developing treatments for Duchenne muscular dystrophy (DMD), including RNA-based therapies and gene therapies [8].